With the passing of Pinuccia Valagussa, co-founder of the Michelangelo Foundation, the field of medicine loses one of the key figures of a season that set the stage of modern clinical oncology

A new review from Italian researchers summarizes evidence of efficacy of PARP inhibitors, focusing on potential new applications and the future of clinical research with these agents

The final analysis of phase III PEONY trial confirms a positive benefit/risk ratio of neoadjuvant/adjuvant pertuzumab, trastuzumab, and docetaxel treatment in patients with HER2+ early breast cancer

Results from the NATALEE trial show disease-free survival benefits with ribociclib added to aromatase inhibitors compared to hormone therapy alone

INAVO120 trial primary analysis shows benefits with inavosilib added to palbociclib and fulvestrant in PIK3CA-mutant locally advanced or metastatic breast cancer

Higher pathologic complete response rate with atezolizumab added to anthracycline and cyclophosphamide and chemotherapy plus trastuzumab/pertuzumab in HER2+ breast cancer